Axogen, Inc. Common Stock

AXGN trades at an extremely lofty RSI of 72.7, deep into overbought territory, yet the stock hasn't reached its 52-week high—a peculiar disconnect suggesting recent momentum without conviction at previous peaks. The $2.3B market cap company trades without a meaningful P/E ratio, indicating either minimal profitability or losses, which raises red flags about the sustainability of its current valuation. With 8.12% short interest, there's meaningful skepticism from bears, though not enough to indicate an imminent squeeze. The overbought RSI combined with unprofitable fundamentals creates a precarious setup where mean reversion risk appears substantial, particularly if revenue growth disappoints.